Analytical Data
-
Gene name
AGR3
- Application
-
Alternative Names
rHuAG-3, His; HAG-3; AGR3; AG3; Anterior gradient protein 3
-
Species
Human
-
Source
HEK293
-
Tag
C-6*His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q8TD06
-
Expression Region
I22-L166
-
Protein Length
Full Length of Mature Protein
-
Molecular Weight
16.0 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
AGR3 (anterior gradient 3) is a protein that has garnered significant attention in the field of cancer research due to its potential role in tumorigenesis and the progression of various malignancies, particularly breast cancer. Originally identified as a developmental protein, AGR3 is thought to be involved in the regulation of cell proliferation, differentiation, and survival. Its expression is often upregulated in cancerous tissues, suggesting that it may function as a biomarker for disease progression. Moreover, AGR3 has been implicated in the modulation of the ER (estrogen receptor) signaling pathway, which plays a critical role in hormone-dependent cancers. Research has shown that AGR3 can influence the response of tumors to hormonal therapies, making it a target of interest for therapeutics aimed at overcoming treatment resistance. The study of recombinant AGR3 proteins, including their structural and functional characteristics, has advanced our understanding of its precise biological roles, interactions with other cellular proteins, and potential as a therapeutic target. This research trajectory not only contributes to basic science but also has important implications for developing more effective strategies for cancer diagnosis and treatment, highlighting AGR3's relevance in the search for novel cancer therapies. Through ongoing investigations into AGR3, we aim to unravel its mechanisms in tumor biology, which may lead to innovative approaches for tackling resistant cancer forms and improving patient outcomes.
